Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-Dose Capecitabine in Metastatic Breast Cancer
NCT00274768Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2004
- Primary completion
- Dec 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Response Rate. Started Apr 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00274768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274768.